| Michael J Bozivich, MD | |
|
17 Exchange St W, Suite 500, Saint Paul, MN 55102-1045 | |
| (651) 232-4200 | |
| (651) 232-4119 |
| Full Name | Michael J Bozivich |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 47 Years |
| Location | 17 Exchange St W, Saint Paul, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023073913 | NPI | - | NPPES |
| 579203700 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 24050 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Healtheast St John's Hospital | Maplewood, MN | Hospital |
| Healtheast Woodwinds Hospital | Woodbury, MN | Hospital |
| Allina United Hospital | Saint paul, MN | Hospital |
| University Of Minnesota Medical Center, Fairview | Minneapolis, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healtheast Medical Research Institute | 3971407636 | 500 |
News Archive
A new study has important implications for the millions of African Americans who suffer from high blood pressure. The study, AADVANCE, shows Diovan HCT(R) (valsartan and hydrochlorothiazide) lowers blood pressure in African Americans to aggressive recommended target blood pressure goals as effectively as amlodipine.
Medical researchers have a critical role to play in gaining optimal health insurance reimbursement for MR-guided focused ultrasound. As Susan Klees, Director of Patient Access for the Focused Ultrasound Surgery Foundation, reports, "Scientific evidence is the key driver for reimbursement, and it all begins with the way studies are designed. Today, research priorities must be grounded in sound science as well as the realities of the marketplace."
The University of Reading is participating in a landmark study to identify the best dietary strategies to reduce heart disease and Type 2 diabetes.
ExonHit Therapeutics today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer's disease, in the journal Current Alzheimer Research.
› Verified 8 days ago
| Entity Name | Healtheast Woodwinds Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356309322 PECOS PAC ID: 9638082563 Enrollment ID: O20031107000110 |
News Archive
A new study has important implications for the millions of African Americans who suffer from high blood pressure. The study, AADVANCE, shows Diovan HCT(R) (valsartan and hydrochlorothiazide) lowers blood pressure in African Americans to aggressive recommended target blood pressure goals as effectively as amlodipine.
Medical researchers have a critical role to play in gaining optimal health insurance reimbursement for MR-guided focused ultrasound. As Susan Klees, Director of Patient Access for the Focused Ultrasound Surgery Foundation, reports, "Scientific evidence is the key driver for reimbursement, and it all begins with the way studies are designed. Today, research priorities must be grounded in sound science as well as the realities of the marketplace."
The University of Reading is participating in a landmark study to identify the best dietary strategies to reduce heart disease and Type 2 diabetes.
ExonHit Therapeutics today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer's disease, in the journal Current Alzheimer Research.
› Verified 8 days ago
| Entity Name | Healtheast Medical Research Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639125503 PECOS PAC ID: 3971407636 Enrollment ID: O20031124000507 |
News Archive
A new study has important implications for the millions of African Americans who suffer from high blood pressure. The study, AADVANCE, shows Diovan HCT(R) (valsartan and hydrochlorothiazide) lowers blood pressure in African Americans to aggressive recommended target blood pressure goals as effectively as amlodipine.
Medical researchers have a critical role to play in gaining optimal health insurance reimbursement for MR-guided focused ultrasound. As Susan Klees, Director of Patient Access for the Focused Ultrasound Surgery Foundation, reports, "Scientific evidence is the key driver for reimbursement, and it all begins with the way studies are designed. Today, research priorities must be grounded in sound science as well as the realities of the marketplace."
The University of Reading is participating in a landmark study to identify the best dietary strategies to reduce heart disease and Type 2 diabetes.
ExonHit Therapeutics today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer's disease, in the journal Current Alzheimer Research.
› Verified 8 days ago
| Entity Name | Healtheast St Joseph's Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134186273 PECOS PAC ID: 2365348869 Enrollment ID: O20031208000245 |
News Archive
A new study has important implications for the millions of African Americans who suffer from high blood pressure. The study, AADVANCE, shows Diovan HCT(R) (valsartan and hydrochlorothiazide) lowers blood pressure in African Americans to aggressive recommended target blood pressure goals as effectively as amlodipine.
Medical researchers have a critical role to play in gaining optimal health insurance reimbursement for MR-guided focused ultrasound. As Susan Klees, Director of Patient Access for the Focused Ultrasound Surgery Foundation, reports, "Scientific evidence is the key driver for reimbursement, and it all begins with the way studies are designed. Today, research priorities must be grounded in sound science as well as the realities of the marketplace."
The University of Reading is participating in a landmark study to identify the best dietary strategies to reduce heart disease and Type 2 diabetes.
ExonHit Therapeutics today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer's disease, in the journal Current Alzheimer Research.
› Verified 8 days ago
| Entity Name | Healtheast St John's Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447218482 PECOS PAC ID: 9234035742 Enrollment ID: O20031208000320 |
News Archive
A new study has important implications for the millions of African Americans who suffer from high blood pressure. The study, AADVANCE, shows Diovan HCT(R) (valsartan and hydrochlorothiazide) lowers blood pressure in African Americans to aggressive recommended target blood pressure goals as effectively as amlodipine.
Medical researchers have a critical role to play in gaining optimal health insurance reimbursement for MR-guided focused ultrasound. As Susan Klees, Director of Patient Access for the Focused Ultrasound Surgery Foundation, reports, "Scientific evidence is the key driver for reimbursement, and it all begins with the way studies are designed. Today, research priorities must be grounded in sound science as well as the realities of the marketplace."
The University of Reading is participating in a landmark study to identify the best dietary strategies to reduce heart disease and Type 2 diabetes.
ExonHit Therapeutics today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer's disease, in the journal Current Alzheimer Research.
› Verified 8 days ago
| Entity Name | Healtheast Care System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194787465 PECOS PAC ID: 7214833763 Enrollment ID: O20031208000483 |
News Archive
A new study has important implications for the millions of African Americans who suffer from high blood pressure. The study, AADVANCE, shows Diovan HCT(R) (valsartan and hydrochlorothiazide) lowers blood pressure in African Americans to aggressive recommended target blood pressure goals as effectively as amlodipine.
Medical researchers have a critical role to play in gaining optimal health insurance reimbursement for MR-guided focused ultrasound. As Susan Klees, Director of Patient Access for the Focused Ultrasound Surgery Foundation, reports, "Scientific evidence is the key driver for reimbursement, and it all begins with the way studies are designed. Today, research priorities must be grounded in sound science as well as the realities of the marketplace."
The University of Reading is participating in a landmark study to identify the best dietary strategies to reduce heart disease and Type 2 diabetes.
ExonHit Therapeutics today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer's disease, in the journal Current Alzheimer Research.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael J Bozivich, MD 17 Exchange St W, Suite 500, Saint Paul, MN 55102-1045 Ph: (651) 232-4200 | Michael J Bozivich, MD 17 Exchange St W, Suite 500, Saint Paul, MN 55102-1045 Ph: (651) 232-4200 |
News Archive
A new study has important implications for the millions of African Americans who suffer from high blood pressure. The study, AADVANCE, shows Diovan HCT(R) (valsartan and hydrochlorothiazide) lowers blood pressure in African Americans to aggressive recommended target blood pressure goals as effectively as amlodipine.
Medical researchers have a critical role to play in gaining optimal health insurance reimbursement for MR-guided focused ultrasound. As Susan Klees, Director of Patient Access for the Focused Ultrasound Surgery Foundation, reports, "Scientific evidence is the key driver for reimbursement, and it all begins with the way studies are designed. Today, research priorities must be grounded in sound science as well as the realities of the marketplace."
The University of Reading is participating in a landmark study to identify the best dietary strategies to reduce heart disease and Type 2 diabetes.
ExonHit Therapeutics today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer's disease, in the journal Current Alzheimer Research.
› Verified 8 days ago
Wojciech Kraszkiewicz, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-3456 Fax: 651-254-9673 | |
Nicholas Charles Boysen, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-3456 Fax: 651-254-9673 | |
Nathan M Frink, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1690 University Ave W, Suite 570, Saint Paul, MN 55104 Phone: 651-232-4800 Fax: 651-232-4899 | |
Dr. Andrew Caraganis, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 Phalen Blvd, Saint Paul, MN 55130 Phone: 651-254-7670 Fax: 651-254-7676 | |
Dr. Patrick George Manning, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-4887 Fax: 651-254-1603 | |
Anthony Williams, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 640 Jackson St, Saint Paul, MN 55101 Phone: 651-254-3456 Fax: 651-254-9673 | |
Samantha May Scheid, Internal Medicine Medicare: Medicare Enrolled Practice Location: 401 Phalen Blvd, Saint Paul, MN 55130 Phone: 651-254-7980 |